Lipid phosphatase SAC1 suppresses hepatocellular carcinoma metastasis by attenuating YAP-mediated integrin expression
Metastasis is the primary cause of recurrence and mortality in hepatocellular carcinoma (HCC); however, the underlying molecular mechanisms remain to be fully elucidated. SAC1/SACM1L, a SAC1-like phosphoinositide phosphatase that dephosphorylates phosphatidylinositol-4-phosphate (PI4P), is downregulated in metastatic breast and prostate cancers. However, its role in HCC tumorigenesis and metastasis remains unexplored. The potential role of SAC1 in HCC tumorigenesis/metastasis was investigated in vitro using HCC cell lines and in vivo using BALB/c nude mouse models established via tail vein injection or orthotopic liver implantation of HCC cells. Our study revealed that decreased SAC1 levels correlate with tumor metastasis and poor prognosis in patients with HCC. Silencing of SAC1 did not significantly affect proliferation but promoted migration and invasion in MHCC97H and PLC/PRF/5 HCC cells. Conversely, SAC1 overexpression suppressed these metastatic phenotypes. Stable overexpression of SAC1 in MHCC97H cells significantly reduced lung metastatic burden in BALB/c nude mice following tail vein injection or orthotopic liver implantation. Mechanistically, SAC1 suppresses HCC metastasis by downregulating the expression of integrins, including ITGA2, ITGAV, and ITGB6. SAC1 attenuates YAP-mediated integrin expression via a two-level mechanism: it hydrolyzes PI4P to activate the NF2/Hippo signaling axis, leading to YAP phosphorylation and inhibition of its nuclear localization; SAC1 also facilitates the interaction between 14-3-3 proteins and phosphorylated YAP, thereby promoting its cytoplasmic retention and inhibiting integrin expression. Collectively, our findings establish that SAC1 functions as a novel inhibitor of HCC metastasis through attenuating YAP-mediated integrin expression, suggesting its potential as both a potential prognostic biomarker and a candidate therapeutic target for metastatic HCC.
Authors
- Wanyu Deng (ORCID: https://orcid.org/0000-0001-7789-3861)
- Sichen Luo
- Yong Lin (ORCID: https://orcid.org/0000-0001-9171-0195)
- Hecun Zou (ORCID: https://orcid.org/0000-0001-7902-7385)
- Dan Xu (ORCID: https://orcid.org/0000-0001-6164-2056)
- Ning Jiang (ORCID: https://orcid.org/0000-0002-5784-8622)
- Haoran Tang (ORCID: https://orcid.org/0009-0004-4716-7585)
- Mengji Lu (ORCID: https://orcid.org/0000-0003-4287-9941)
- Hongyu Deng (ORCID: https://orcid.org/0009-0007-9047-7898)
- Wen Shu
- Beinu Guo
- Tianyu Chen
- Qian Liu
- Zhen Wei
- Mengting Liu
- Jiang Min
- Jie Xia
Institutions
- Shangrao Normal University (CN)
- Central South University (CN)
- Hunan Cancer Hospital (CN)
- Essen University Hospital (DE)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- University of Duisburg-Essen (DE)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1186/s12967-026-09235-2
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00